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Aminoglycosides presently constitute ¢rst-line antibacterial
therapy, particularly in high-risk patients with serious and
life-threatening aerobic Gram-negative infections. However,
aminoglycosides continue to manifest undesirable side-e¡ects
such as nephrotoxicity, complicating 5^35% of therapeutic
courses. The incidence of these side-e¡ects can be reduced
when appropriate attention is paid to the dose of the drug, the
duration of therapy, the avoidance of dehydration and hypoka-
lemia, and the speci¢c aminoglycoside selected for therapy.
Actually, there is continuing debate over the most appropriate
administration regimen for these drugs. Aminoglycosides
have been administered in twice- or thrice-daily dosing regi-
mens since their introduction to clinical use four decades ago.
Recently, increasing numbers of experimental and clinical
studies have demonstrated that a once-daily dosing regimen
may be at least as e¡ective as, and possibly less toxic than mul-
tiple dosing. It seems essential to achieve high peak concentra-
tions, since the bactericidal activity of the aminoglycosides is
concentration-dependent and the ratio of the peak concentra-
tion to the MIC correlates closely with therapeutic outcome
[1^4].
The risk for the development of aminoglycoside-induced
nephrotoxicity has been well de¢ned with multiple dosing
regimens, including dose, duration of therapy longer than 10
days, dehydration, hypokalemia, severe obesity with incorrect
dosage calculations, elderly patients, concurrent nephrotoxic
agents, prior aminoglycoside therapy (particularly within 6
weeks), underlying disease, pre-existing renal failure and the
type of aminoglycoside used [5^9]. Most of these risk factors
need to be re-evaluated with a once-daily regimen.The dura-
tion of aminoglycoside therapy, with a cut-o¡ point at 6 or 7
days, and the cumulative dose are recognized in both uni- and
multivariate analysis as strong and well documented toxicity
factors even if individualized pharmacokinetic monitoring is
used [10^22]. High serum peak concentrations in the very
elderly population, and administration of aminoglycosides
during patients' rest periods, may also favor nephrotoxicity
[23^25].
The role of individual aminoglycoside selection has not
been clearly evaluated during once-daily regimens, and thus it
is not known if aminoglycoside-induced nephrotoxicity pre-
vention by once-daily dosing applies equally to all aminogly-
cosides.
R A T I O N A L E F O R O N C E - D A I L Y D O S I N G
After parenteral administration, aminoglycosides are elimi-
nated almost entirely via the kidney by glomerular ¢ltration.
However, a fraction of aminoglycosides is reabsorbed in the
proximal tubule. Rate-limiting binding of these polycationic
antibiotics takes place at various phosphoinositol-binding
sites on the proximal tubular cell brush border. An additional
fraction of drug enters proximal tubular cells through a baso-
lateral cell transport system. Aminoglycosides accumulate
within lysosomes. During repetitive dosing with aminogly-
cosides, lysosomes continuously take drugs upwith a progres-
sive size increase. The loss of their restricting membrane
integrity, their disruption and the liberation of proteolytic
enzymes and aminoglycosides into the cell cytosol lead to cell
necrosis and renal failure. Under conventional dosing, the kid-
ney is unable to totally excrete the aminoglycoside dose within
the dosing interval related to impaired function. This point
has led to the evaluation of once-daily dosing of aminoglyco-
sides, which would take advantage of minimizing repeated
exposure and therefore potential nephrotoxicity.
The impact of dose scheduling on renal toxicity can be
explained by non-linear drug accumulation. Uptake of ami-
noglycosides into renal tissue is not proportional to the con-
centration over the entire range of serum levels encountered
during once-daily dosing, and is limited by a saturation
mechanism. The penetration velocity into tubular cells
becomes slower when serum concentration reaches 10^15mg/
L [26], values regularly exceeded when aminoglycosides are
used once daily, especially with netilmicin, amikacin and ise-
pamicin. Due to drug-speci¢c saturable uptake, high peak
levels are not critical for renal accumulation [26^28]. Accord-
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ing to these data, aminoglycoside-induced nephrotoxicity is
not primarily associated with high peak levels present for a
limited period of time. Conversely, elevated trough concen-
trations, over 2mg/L for gentamicin and tobramycin, have
been associated with nephrotoxicity [29^31]. The prolonged
time period with low serum concentrations and the lower
trough values achieved with once-daily dosing may therefore
result in a lower total amount of accumulated drug compared
to fractionated dosing.
Toxicologic studies in animals have clearly demonstrated
that dividing the total daily dose into several smaller doses
causes more frequent and severe renal toxicity compared to
once-daily administration [32^35]. In humans, the amount of
netilmicin or gentamicin accumulated in the kidneys is 30^
50% higher after continuous infusion (even if this regimen is
never used in humans) compared to once-daily administra-
tion of the same total dose [28,36^38]. However, no study has
compared renal accumulation of aminoglycosides after single
daily dosing compared to multiple daily dosing [39]. Finally,
the risk of nephrotoxicity does not disappear with once-daily
regimens, but this risk is delayed and appears 3 days later com-
pared to fractionated dosing [40].
S P EC I F I C A M I N O G LY C O S I D E SE L E CT I O N
Multiple daily dosing
Extensive comparative clinical trial data have been published
with fractionated conventional use of aminoglycosides.
Twenty-¢ve years ago, Whelton [41] summarized the most
important studies related to aminoglycoside-induced nephro-
toxicity (Table1). Study methodology varied from study to
study and few of them followed a double-blind protocol.
Nephrotoxicity was generally determined using rather non-
sensitive end-points such as measurement of serum creatinine.
Nevertheless, the analysis of these clinical trial data con¢rmed
that, in conventional schedules, gentamicin and tobramycin
were signi¢cantly more nephrotoxic than amikacin and netil-
micin, and that amikacin and netilmicin were comparable.
This has been con¢rmed in a human study [42] comparing
lysosomal morphology and function in proximal tubular cells
4 days after amikacin, gentamicin and tobramycin administra-
tion. Gentamicin and tobramycin could not be distinguished
on the basis of drug tissue accumulation, lysosomal overload-
ing, or e¡ect on lysosomal phospholipase A1, while amikacin
induced signi¢cantly lower lysosomal overloading and no loss
of phospholipase A1 activity. This di¡erence in nephrotoxic
potential among aminoglycosides could be related to their
chemical structure and more precisely to their ability to bind
to the brush bordermembranes [43,44].
Single daily dosing
In the last 10 years, the e¡ects of the single daily dosing of ami-
noglycosides on toxicity and e¤cacy have been evaluated in
many randomized comparative clinical studies. The majority
of them failed to demonstrate clearly a real bene¢t of this regi-
men. Since 1994, several meta-analyses [13^21] have been pub-
lished, providing information on the evaluation of single daily
dosing of aminoglycosides.This regimen appears to be clearly
associated with a decrease in the nephrotoxicity incidence.
These apparent good results may have been minimized by a
relatively prolonged duration of treatment with aminoglyco-
sides performed in all these studies (generally from 7 to 10
days). Actually, it has been pointed out that the nephrotoxic
risk was higher when the treatment with aminoglycosides was
prolonged above 6^7 days [11,12]. In addition, most of these
meta-analyses did not evaluate the bene¢t of the single daily
dosing according to the nephrotoxic potential of the di¡erent
aminoglycosides.
Gentamicin, netilmicin, and amikacin
Only twometa-analyses emphasized aminoglycoside nephro-
toxic risk on a family basis. In the meta-analyses published by
Blaser and Konig [13], a total of 24 randomized prospective
clinical trials comparing multiple and single daily dosing of
amikacin, gentamicin, netilmicin, or tobramycin were
Table 1 Nephrotoxic potential of aminoglycosides with conventional use [41]
Aminoglycoside
Patients
n
Nephrotoxicity
n
%
mean (range)
Amikacin (A) 733 63 8.6 (0±27.6)
Gentamicin (G) 1055 163 15.5 (2.0±55.2)
Netilmicin (N) 256 19 7.4 (1.0±38.2)
Tobramycin (T) 709 98 13.8 (5.8±58.0)
G versus A: P0.00002; RR1.26 (CI 95 : 1.15±1.38). G versus T: P 0.34. G versus N: P0.0009; RR 1.13 (CI 95 : 1.07±1.20). T versus A:
P0.002; RR1.28 (CI 95 : 1.11±1.46). T versus N: P 0.007; RR 1.16 (CI 95 1.06±1.27). A versus N: P0.55.
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pooled. In these trials, the de¢nition of a potentially signi¢-
cant change in the serum creatinine value ranged fromr20%
to r50%, or from r30 to r45 mmol/L increase from base-
line. In most trials, no signi¢cant di¡erence between the regi-
mens was detected. The overall analysis of the 3181 patients
enrolled in this meta-analysis (Table 2) revealed no signi¢cant
di¡erence between single andmultiple dailydosing. However,
therewas a trend towards less nephrotoxicity in the once-daily
treatment groups (4.5% versus 5.5%). More precisely, the
authors con¢rmed that the renal tolerance of gentamicin was
signi¢cantly improvedwhen it was used once-daily (P 0.02;
RR 0.51). But when the data from this meta-analysis are
carefully analyzed, some results need to be pointed out: (1)
gentamicin delivered in multiple daily doses was signi¢cantly
more nephrotoxic than amikacin (P 0.0002; RR 2.53),
but no di¡erence was observed compared to netilmicin, as
opposed to the analysis of Whelton [34]; (2) when delivered
in multiple daily doses, amikacin appeared signi¢cantly less
nephrotoxic than netilmicin (P 0.00008; RR 0.60), as
well as netilmicinwhen delivered once daily (P 0.02; RR
0.75); (3) neither netilmicin nor amikacin showed signi¢cant
bene¢t of single daily dosing regarding renal toxicity; (4)
when delivered once daily, gentamicin and amikacin renal
tolerance was similar (P 0.9), and relatively low (3.5%).
Finally, onlygentamicin, because of an important nephrotoxic
potential, exhibits a bene¢t frombeing used once daily.
Munckhof et al [18] have described similar results. The
pooled data of 15 studies involving 2295 evaluable patients
showed an overall rate of nephrotoxicity of 4.7% and 5.9%
after, respectively, once and multiple daily dosing.When both
studies involving gentamicinwere pooled, with a total of only
111 patients, a marked decrease in the rate of nephrotoxicity
was demonstratedwhen the drug was given once daily. On the
contrary, among the larger groups of 788 and 1396 patients
who received, respectively, netilmicin or amikacin, there was
no signi¢cant di¡erence in the rate of nephrotoxicity between
once andmultiple daily dosing.
Some studies have con¢rmed that preservation of renal
functionwas better in gentamicin once-a-day patients than in
gentamicin three-times-a-day patients [31,45,46]. When
delivered once daily, gentamicin does not appear more
nephrotoxic than netilmicin [12,47]. In the experience of the
Hartford Hospital, more than 2000 patients have been treated
with gentamicin once daily with a ¢xed 7mg/kg intravenous
dose.The incidence of nephrotoxicity was reduced from about
4% with conventional dosing to 1.2% [48,49]. This once-a-
day program reduced the incidence of nephrotoxicity, andwas
cost-e¡ective, with nephrotoxicity management savings of
70% per patient [50].
Isepamicin and amikacin
The chemical structure of isepamicin, a 1-N-S-a-hydroxy-b-
aminopropionyl derivative of gentamicin B, is very close to
that of gentamicin. The nephrotoxic potential of isepamicin
delivered once and twice dailywas comparedwith that of ami-
kacin delivered twice daily in a few studies. In a prospective
randomized trial [51], e¤cacy and safety of isepamicin were
compared with those of amikacin in 168 ICU adult patients
with nosocomial pneumonia or septicemia. Each studied ami-
noglycoside was administered concurrently with ceftazidime
or imipenem. Patients were randomized to receive isepamicin
15mg/kg per day, once daily (n 56) or twice daily (n 55),
or amikacin 15mg/kg per day, twice daily (n 57). The de¢-
nition of a potentially signi¢cant change in the serum creati-
nine value was a r0.5mg/dL (44.2 mmol/L) increase from
baseline, and any increase above the upper limit of the normal
range. The proportion of patients reporting at least one treat-
ment-related adverse event (Table 3) was higher in the isepa-
micin twice-daily group than in the isepamicin once-daily
group, and signi¢cantly higher than in the amikacin twice-
daily group (P 0.04; RR1.74), while there was no di¡er-
ence between the isepamicin once-daily group and the amika-
cin twice-daily group. Renal toxicity was one of the most
frequently reported adverse events. An increase in serum crea-
Table 2 Contribution of single daily dosing of aminoglycosides to the decrease of their nephrotoxic potential [13]
Incidence of nephrotoxicity with:
Aminoglycosides Single daily dosing (SDD) Multiple daily dosing (MDD)
All (24 studies) 73/1617 (4.5%) 86/1564 (5.5%)
Amikacin (A, 7 studies) 30/851 (3.5%) 25/817 (3.1)
Gentamicin (G, 4 studies) 6/183 (3.3%) 15/153 (9.8%)
Netilmicin (N, 13 studies) 37/583 (6.3%) 46/594 (7.7%)
G MDD versus A MDD: P 0.0002; RR 2.53 (CI 95 : 1.65±3.88). G MDD versus N MDD: P0.69. A MDD versus N MDD: P0.00008; RR
0.60 (CI 95 : 0.43±0.82). G SDD versus G MDD: P 0.02; RR0.51 (CI 95 : 0.26±1.01). A SDD versus A MDD: P0.3. N SDD versus N MDD:
P 0.9. G SDD versus A SDD: P 0.9. G SDD versus N SDD: P 0.2. A SDD versus N SDD: P 0.02; RR 0.75 (CI 95 : 0.57±0.98).
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tinine, considered by the investigator to be treatment-related,
was noted in none of the patients receiving isepamicin once-
daily, three patients (8%) receiving isepamicin twice-daily
and three patients (7%) receiving amikacin twice-daily. The
proportion of patients reporting renal failure and renal insu¤-
ciency as a treatment-related adverse event was higher, close to
the limit of signi¢cance, in the isepamicin twice-daily, com-
pared to the isepamicin once-daily, group (P 0.056) and the
amikacin twice-daily group (P 0.054), while there was no
di¡erence between the isepamicin once-daily group and the
amikacin twice-daily group. Finally, in this study, it could be
emphasized that the renal tolerance of isepamicin was
improved when used once daily, compared to twice-daily
administration. This study con¢rmed the real nephrotoxic
potential of isepamicin.
In an overview of the safety of isepamicin in adults [52],
comparing di¡erent regimens of isepamicin and amikacin in
1243 and 552 patients, respectively, receiving a ¢xed 15mg/kg
per day dose, some di¡erences appeared concerning the renal
tolerance of isepamicin when delivered once or twice daily
(Table 4).When all the patients treated with isepamicin were
compared with those treated with amikacin, the rate of treat-
ment-related adverse events was similar in the two groups
(11% versus 9%). An analysis strati¢ed on the di¡erent regi-
mens showed a signi¢cant di¡erence favoring the twice-daily
regimen of amikacin over the twice-daily regimen of isepami-
cin (P 0.03; RR1.71). No di¡erence was noted between
the patients treated with isepamicin once or twice daily, or
between the patients treated with isepamicin once daily or
amikacin twice daily.With respect to the nephrotoxicity rate,
there was a signi¢cant di¡erence favoring the once-daily regi-
men of isepamicin compared to the twice-daily regimen (P
0.01; RR 0.57), and the twice-daily regimen of amikacin
compared to the twice-daily regimen of isepamicin (P 0.05;
RR 2.70). No di¡erence was noted between the patients
treated with isepamicin once daily or amikacin twice daily.
Details concerning the serum creatinine increase in the di¡er-
ent groups of patients were not available. Finally, in this over-
viewof the safety of isepamicin, it should be emphasized again
that the renal tolerance of isepamicinwas improvedwhen used
once daily, compared to twice-daily administration.
Finally, isepamicin, like gentamicin, and because of its
nephrotoxic potential, bene¢ts from once-daily dosing,
appearing to be less nephrotoxic. Isepamicin delivered twice
daily is signi¢cantly more nephrotoxic than amikacin deliv-
ered twice daily. No data comparing the nephrotoxicity of ise-
pamicin and amikacin when both are delivered once daily are
available.
C O N C L U S I O N
Better knowledge of the risk factors associated with the renal
toxicity of aminoglycosides, a reduction in the number of
daily injections of aminoglycosides, minimization of the ther-
Table 3 Comparison of isepamicin and amikacin nephrotoxic potential according to the daily dosing [51]
Isepamicin (I) Amikacin (A)
Adverse events
Once a day
(n = 56)
Twice a day
(n = 55)
Twice a day
(n = 57)
Treatment-related adverse events 3 (5.4%) 8 (14.5%)a 2 (3.5%)a
Serum creatinine increase 0 3 (8%) 3 (7%)
Renal compromise 0b 4 (7.3%)b,c 0c
aP = 0.04; RR = 1.74 (CI 95 : 1.19±2.52). bP = 0.056. cP = 0.054.
Table 4 Comparison of isepamicin and amikacin nephrotoxic potential according to the daily dosing [52]
Isepamicin (I) Amikacin (A)
Adverse events
Once a day
(n = 686)
Twice a day
(n = 99)
Twice a day
(n = 552)
Treatment-related adverse events 73 (11%) 16 (16%)a 50 (9%)a
Serum creatinine increase ND ND 26 (5.1%)
Renal compromise 4 (0.6%)b 4 (4%)b,c 6 (1.1%)c
aP = 0.03; RR = 1.71 (CI 95 : 1.07±2.74). bP = 0.01; RR = 0.57 (CI 95 : 0.28±1.14). cP = 0.05; RR = 2.70 (CI 95 : 1.24±5.90).
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apy duration, and the administration of aminoglycosides at
the time of the lowest toxicity of the drug in patients given an
appropriate diet are the most interesting approaches to reduce
the incidence of these agents' renal toxicity [53,54]. Moreover,
individualized dosing based on individual patient parameters
and population models [55], and individualized pharmacoki-
netic monitoring, are promising to decrease the rate of amino-
glycoside-related nephrotoxicity [39].
However, every aminoglycoside shows a speci¢c nephro-
toxic potential. Tobramycin, gentamicin, and isepamicin
appear more nephrotoxic than netilmicin, and much more
than amikacin. Finally, only gentamicin and isepamicin exhi-
bit a bene¢t of being used once-daily to decrease the nephro-
toxic risk.
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